Paediatric infectious diseases
Menarini Ricerche S.p.A. is involved in clinical research for suspected or confirmed Gram negative infections in paediatric patients, with attention to serious infectious conditions requiring hospital-based care.
- Gram negative infections
- Paediatric infection management
- Serious bacterial infections
The sponsor’s research interest in this area centres on infection treatment in children from birth through adolescence, reflecting a focus on vulnerable age groups affected by severe bacterial disease.
Antibacterial therapy
The clinical programme includes evaluation of meropenem and vaborbactam within the context of antibacterial treatment for difficult-to-manage infections, highlighting interest in combination approaches for resistant pathogens.
- Carbapenem-based treatment
- Beta-lactamase inhibition
- Combination antibacterial therapy
This area aligns with therapeutic development for infections where broad-spectrum antibacterial coverage and resistance-targeted strategies are clinically relevant.
Pharmacokinetics and drug exposure
Menarini Ricerche S.p.A. is studying how the antibacterial regimen is taken up in the body in paediatric participants, with emphasis on pharmacokinetic behaviour across early life stages.
- Drug disposition
- Systemic exposure
- Infant and adolescent pharmacology
These research interests are relevant to understanding age-related differences in handling anti-infective treatments in children.
Hospital infectious disease care
The sponsor’s trial activity extends across multiple countries and collaborating sites, supporting research in acute infectious disease settings where treatment of serious bacterial infections is a priority.
- Multisite paediatric care
- Acute infection treatment
- Clinical anti-infective use
This research area reflects involvement in therapeutic questions relevant to specialised centres managing complex bacterial infections in children.
